Evidence map›Paper›PMID 30206413›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

Genetic and molecular reappraisal of spindle cell adamantinoma of bone reveals a small subset of misclassified intraosseous synovial sarcoma.

Andrew Horvai, Nooshin K Dashti, Brian P Rubin, Scott E Kilpatrick, Erin R Rudzinski, Dolores Lopez-Terrada, Mary B Hubley, Jessica L Davis, Karen Fritchie

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Tibial Adamantinoma: A Case Report from a Resource-Limited-Setting.International medical case reports journal · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Adamantinoma: An Updated Review.In vivo (Athens, Greece)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Andrew HorvaiDepartment of Pathology, University of California, San Francisco, 1825 4th Street M2354, San Francisco, CA, 94143, USA. Andrew.horvai@ucsf.edu.
Nooshin K DashtiDepartment of Pathology, Mayo Clinic, Rochester, MN, USA.
Brian P RubinDepartment of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Scott E Kilpatrick
Erin R RudzinskiDepartment of Laboratories, Seattle Children's Hospital, Seattle, WA, USA.
Dolores Lopez-TerradaDepartment of Pathology, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, 77030, USA.
Mary B HubleyDepartment of Pathology, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, 77030, USA.
Jessica L DavisDepartment of Pathology, Oregon Health and Science University, Portland, OR, 97239, USA.
Karen FritchieDepartment of Pathology, Mayo Clinic, Rochester, MN, USA.
Baylor College of Medicine · USMayo Clinic in Arizona · USUniversity of California, San Francisco · USCleveland Clinic · USOregon Health & Science University · USSeattle Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adamantinoma represents a distinct group of bone tumors showing both mesenchymal and epithelial differentiation most commonly involving the tibial diaphysis. Most adamantinomas contain a fibro-osseous component and an epithelial component consisting of squamous or basaloid cells. Adamantinomas are considered malignant neoplasms requiring en bloc excision that frequently recur locally and can rarely metastasize. Rare adamantinomas show an epithelial component consisting predominantly of monomorphic spindle cells, which, combined with an epithelial immunophenotype, can mimic monophasic synovial sarcoma. Synovial sarcoma is very rare in bone. It is considered a high-grade sarcoma that typically necessitates chemotherapy. However, the relationship between spindle cell adamantinoma and intraosseous synovial sarcoma has not been investigated. The current study was prompted by identification of a presumed spindle cell adamantinoma of the tibia with diffuse keratin expression that harbored a SS18 gene region rearrangement. FISH of eight additional bone tumors initially classified as spindle cell adamantinoma based on clinicoradiopathologic findings revealed one additional case with SS18 rearrangement. Histologically, both intraosseous synovial sarcoma and spindle cell adamantinoma demonstrated uniform fusiform nuclei with scant cytoplasm, short fascicles and low mitotic activity. The adamantinomas, but not the synovial sarcomas, were more likely to show overt epithelial differentiation in the form of pseudoglands or squamous nests. Immunohistochemistry of all cases, irrespective of SS18 status, showed diffuse keratin positivity in the spindle cell component, and less consistent EMA positivity. Clinical follow-up was available in both intraosseous synovial sarcomas, one of which recurred and the other metastasized. Two of the six spindle cell adamantinomas with follow-up metastasized. The above findings highlight the morphologic and immunophenotypic overlap between spindle cell adamantinoma and intraosseous synovial sarcoma of the tibia. Investigation of SS18 status to exclude synovial sarcoma is suggested prior to rendering a diagnosis of spindle cell adamantinoma.

Indexed as

Diagnostic ErrorsAdamantinomaAdolescentAdultAgedBone NeoplasmsChildFemaleHumansMaleProto-Oncogene ProteinsRepressor ProteinsSarcoma, SynovialProto-Oncogene ProteinsRepressor ProteinsSS18 protein, human

Identifiers

PMID30206413
OpenAlexW2891879732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.